1022P A phase II trial of the IO102-IO103 vaccine plus pembrolizumab: Completed cohort for first-line (1L) treatment of advanced squamous cell carcinoma of the head and neck (SCCHN)Jonathan W. Riess, James Spicer, T. Seiwert et al.|Annals of Oncology|2024Cited by 3